Global NGS Informatics and Clinical Genomics Market: Focus on Product Types (LIMS, Data Analysis and Interpretation Tools, and Storage and Computing Solutions), End Users, and Regional Analysis for 21 Countries, Analysis and Forecast (2018-2028)

1 Market Overview

1.1 Introduction to NGS Informatics and Clinical Genomics
1.2 Cost of NGS Data Analysis
1.3 Role of NGS Informatics in Precision Medicine?
1.4 Approach to Precision Medicine
1.5 Evolution of Precision Medicine Technology
1.6 The Wave of Data Types: NGS Data Remains the Leading Data Type for Precision Medicine
1.6.1 Overview
1.6.2 Genomic Data
1.6.3 Lifestyle and Environment
1.6.4 Health Information
1.6.5 Social Media
1.7 Healthcare Information Technology: A Boon for NGS informatics Market
1.8 The Correlation Between NGS Informatics and Clinical Genomics
1.9 Technologies with the Potential to Incorporate NGS in a Clinical Setting
1.9.1 Electronic Health Records (EHR)
1.9.2 Health Information Exchange
1.9.3 Clinical Decision Support Systems (CDSS)
1.9.4 Population Health Management (PHM)
1.9.5 Blockchain
1.9.6 Artifical Intelligence/Machine Learning
1.9.7 Big Data Analytics

2 Market Dynamics

2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Low cost Sequencing Platforms
2.2.2 Growth in Clinical Application
2.2.3 Rise in Genomic Data
2.2.4 Increasing Number of Population Genomics Initiatives
2.2.5 Advancements in Big Data Technology
2.2.6 Reducing Cost of Cloud Storage
2.3 Market Restraints
2.3.1 Lack of Integration and Interoperability among Existing Information Systems
2.3.2 Patient Access to Data
2.3.3 Data Security and Privacy
2.3.4 Fragmented Research Environment
2.4 Market Opportunities
2.4.1 Cross Industry Collaborations between Health Systems, Academia and Health IT Industry
2.4.2 Investment in Blockchain Technology and Information Security
2.4.3 Clinical Application Focussed NGS Informatics Products
2.4.4 Integration of Clinical and Non-Clinical NGS data
2.4.5 Automation of Sequencing and Interpretation

3 Competitive Insights

3.1 Key Strategies and Developments
3.1.1 Partnerships, Joint Ventures, and Collaborations
3.1.2 Product Development and Launch
3.1.3 Business Funding and Contracts
3.1.4 Mergers and Acquisitions
3.1.5 Approvals and Certifications
3.1.6 Others
3.2 Competitive Scenario: Intense Competition within a Converging Market

4 Industry Attractiveness and Insights

4.1 Porter’s Five Forces Analysis
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyer
4.4 Threat of New Entrants
4.4.1 Threat of Substitute Products
4.4.2 Intensity of Competitive Rivalry

5 Key Industry Insights

5.1 Introduction
5.2 Regulatory Bodies

6 Global NGS Informatics and Clinical Genomics Market: Analysis and Forecast

6.1 Assumptions & Limitations for Market Size Calculations

7 Global NGS Informatics and Clinical Genomics Market (by Technology)

7.1 Overview
7.1.1 Blockchain Genomics Platforms
7.1.2 Data Aggregation Software
7.1.3 AI/Machine Learning and Cloud Computing based Genomic Platforms
7.1.4 Clinical Decision Support based Genomic Platforms
7.1.5 Artificial Intelligence (AI) based Drug Discovery Platforms

8 Global NGS Informatics and Clinical Genomics Market (by Product Type)

8.1 Laboratory Information Management Systems (LIMS)
8.2 NGS Informatics Services (Includes both Sequencing and Consulting Services)
8.3 Commercial Primary and Secondary Data Analysis Tools
8.3.1 Primary Data Analysis
8.3.2 Secondary Data Analysis
8.4 Storage, Infrastructure, and Computing
8.5 Interpretation (Tertiary Analysis) Tools

9 Global NGS Informatics and Clinical Genomics Market (by End User)

9.1 Academics and Research Institutes
9.2 Biopharmaceutical Industry
9.3 Diagnostic Industry
9.4 Government Agencies
9.5 Hospitals and Clinics

10 Global NGS Informatics and Clinical Genomics Market (by Region)

10.1 Overview
10.2 North America
10.2.1 The U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 The U.K.
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest-of-Europe
10.3.6.1 Switzerland
10.4 Asia-Pacific
10.4.1 India
10.4.2 China
10.4.3 Japan
10.4.4 South Korea
10.4.5 Australia
10.4.6 Singapore
10.4.7 Rest-of-Asia-Pacific
10.5 Rest-of-the-World
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Russia
10.5.4 Israel
10.5.5 Other countries in RoW
10.5.5.1 Saudi Arabia
10.5.5.2 United Arab Emirates
10.5.5.3 South Africa

11 Company Profiles

11.1 Overview
11.2 2bPrecise, LLC
11.2.1 Company Overview
11.2.2 Company Overview
11.2.3 Overall Product Portfolio
11.2.4 Product Offerings for Precision Medicine
11.2.5 Financials
11.2.5.1 Financial Summary
11.2.6 Global Presence
11.2.7 Recent Developments
11.2.8 SWOT Analysis
11.3 Cota, Inc.
11.3.1 Company Overview
11.3.2 Product Portfolio
11.3.3 Corporate Summary
11.3.4 Recent Developments
11.3.5 SWOT Analysis
11.4 CureMatch, Inc.
11.4.1 Company Overview
11.4.2 Product Portfolio
11.4.3 Corporate Summary
11.4.4 Global Presence
11.4.5 Recent Developments
11.4.6 SWOT Analysis
11.5 DrChrono Inc.
11.5.1 Company Overview
11.5.2 Overall Product Portfolio
11.5.3 Product Portfolio for Healthcare IT Solutions for Precision Medicine
11.5.4 Corporate Summary
11.5.5 Global Presence
11.5.6 Recent Developments
11.5.7 SWOT Analysis
11.6 Epic Systems Corporation
11.6.1 Company Overview
11.6.2 Overall Product Portfolio
11.6.3 Product Offerings for Precision Medicine
11.6.4 Corporate Summary
11.6.5 SWOT Analysis
11.7 Flatiron Health, Inc. (Subsidiary of Roche Group Company)
11.7.1 Company Overview
11.8 F. Hoffmann-La Roche AG
11.8.1 Company Overview
11.8.2 Overall Product Portfolio
11.8.3 Product Offering
11.8.4 Financials
11.8.4.1 Financial Summary
11.8.5 Global Presence
11.8.6 Recent Developments
11.8.7 SWOT Analysis
11.9 GenomOncology, LLC
11.9.1 Company Overview
11.9.2 Product Portfolio
11.9.3 Corporate Summary
11.9.4 Global Presence
11.9.5 Recent Developments
11.9.6 SWOT Analysis
11.10 Interpreta, Inc.
11.10.1 Company Overview
11.10.2 Product Portfolio
11.10.3 Corporate Summary
11.10.4 Global Presence
11.10.5 Recent Developments
11.10.6 SWOT Analysis
11.11 Illumina, Inc.
11.11.1 Company Overview
11.11.2 Overall Product Portfolio
11.11.3 Product Offering
11.11.4 Financials
11.11.4.1 Financial Summary
11.11.5 Global Presence
11.11.6 Recent Developments
11.11.7 SWOT Analysis
11.12 IBM Corporation
11.12.1 Company Overview
11.12.2 Overall Product Portfolio
11.12.3 Precision Medicine Product Portfolio
11.12.4 Financials
11.12.4.1 Financial Summary
11.12.5 Global Presence
11.12.6 Recent Developments
11.12.7 SWOT Analysis
11.13 Koninklijke Philips N.V.
11.13.1 Company Overview
11.13.2 Overall Product Portfolio
11.13.3 Product Offerings for Precision Medicine
11.13.4 Financials
11.13.4.1 Financial Summary
11.13.5 Global Presence
11.13.6 Recent Developments
11.13.7 SWOT Analysis
11.14 LunaDNA Inc.
11.14.1 Company Overview
11.14.2 Product Portfolio
11.14.3 Corporate Summary
11.14.4 Global Presence
11.14.5 Recent Developments
11.14.6 SWOT Analysis
11.15 Navican Genomics, Inc.
11.15.1 Company Overview
11.15.2 Product Portfolio
11.15.3 Corporate Summary
11.15.4 Global Presence
11.15.5 Recent Developments
11.15.6 SWOT Analysis
11.16 N-of-One, Inc.
11.16.1 Company Overview
11.16.2 Product Portfolio
11.16.3 Corporate Summary
11.16.4 Global Presence
11.16.5 Recent Developments
11.16.6 SWOT Analysis
11.17 NantHealth, Inc.
11.17.1 Company Overview
11.17.2 Overall Product Portfolio
11.17.3 Precision Medicine Product Portfolio
11.17.4 Financials
11.17.4.1 Financial Summary
11.17.5 Global Presence
11.17.6 Recent Developments
11.17.7 SWOT Analysis
11.18 Orion Health Group Limited
11.18.1 Company Overview
11.18.2 Overall Product Portfolio
11.18.3 Product Offerings for Precision Medicine
11.18.4 Financials
11.18.4.1 Financial Summary
11.18.5 Global Presence
11.18.6 Recent Developments
11.18.7 SWOT Analysis
11.19 QIAGEN N.V.
11.19.1 Company Overview
11.19.2 Overall Product Portfolio
11.19.3 Product Offering
11.19.4 Financials
11.19.4.1 Financial Summary
11.19.5 Global Presence
11.19.6 Recent Developments
11.19.7 SWOT Analysis
11.20 SOPHiA GENETICS SA
11.20.1 Company Overview
11.20.2 Product Portfolio
11.20.3 Corporate Summary
11.20.4 Global Presence
11.20.5 Recent Developments
11.20.6 SWOT Analysis
11.21 Syapse, Inc.
11.21.1 Company Overview
11.21.2 Product Portfolio
11.21.3 Corporate Summary
11.21.4 Global Presence
11.21.5 Recent Developments
11.21.6 SWOT Analysis
11.22 SAP SE
11.22.1 Company Overview
11.22.2 Overall Product Portfolio
11.22.3 Product Offerings for Precision Medicine
11.22.4 Financials
11.22.4.1 Financial Summary
11.22.5 Global Presence
11.22.6 Recent Developments
11.22.7 SWOT Analysis
11.23 Tempus Labs, Inc.
11.23.1 Company Overview
11.23.2 Product Portfolio
11.23.3 Corporate Summary
11.23.4 Global Presence
11.23.5 Recent Developments
11.23.6 SWOT Analysis
11.24 Verily Life Sciences LLC
11.24.1 Company Overview
11.24.2 Overall Product Portfolio
11.24.3 Product Offerings for Precision Medicine
11.24.4 Corporate Summary
11.24.5 Global Presence
11.24.6 Recent Developments
11.24.7 SWOT Analysis
11.25 Snapshot of Other Key Industry Players
11.25.1 Beijing Genomic Institute (BGI)
11.25.2 Amazon Web Services, Inc.
11.25.3 DNAnexus, Inc.
11.25.4 DNASTAR
11.25.5 Eagle Genomics
11.25.6 Edico Genome
11.25.7 Genalice
11.25.8 Seven Bridges Genomics Inc.
11.25.9 Fabric Genomics, Inc. (Formerly Omicia, Inc.)
11.25.10 WuxiNextCode
11.25.11 Genomatix AG
11.25.12 Partek Incorporated

12 Research Scope & Methodology

12.1 Report Scope
12.2 NGS Informatics and Clinical Genomics Market: Research Methodology

List of Tables

Table 2.1 Impact Analysis of the Drivers and Challenges in the Market
Table 2.2 Comparison of Data Storage Requirements
Table 5.1 List of Bodies Providing Guidelines Related to Clinical NGS across the World
Table 5.2 List of Policies and Laws
Table 5.3 List of Most Significant Regulatory Authorities that Regulates Medical Devices
Table 5.4 List of Consortiums and Organizations Operating in the Field of Genomics and NGS Informatics
Table 7.1 Commercially Available Blockchain Assisted Genomic Software Platforms
Table 7.2 Types of Clinical Data Generated from Different Forms of Health IT Systems
Table 7.3 Commercially Available Data Aggregation Software
Table 7.4 AI/Machine Learning and Cloud Computing-based Genomic Platforms
Table 7.5 Commercially Available Precision Medicine Oncology Decision Support Companies
Table 7.6 Aggregate and Synthesize Information
Table 8.1 Commercially Available LIMS Software
Table 8.2 NGS Informatics (Sequencing and Consulting) Service Providers
Table 8.3 Commercially Available Primary and Secondary Analysis Tools Providers
Table 8.4 Different Kinds of Commercial Cloud Providers Along with Their Business Models
Table 8.5 Different Kinds of Academic Cloud Providers Along with Their Business Models
Table 8.6 Commercially Available Primary and Secondary Analysis Tools Providers
Table 10.1 ONC's Precision Medicine Initiative Activities
Table 10.2 NGS informatics and Clinical Genomic Service Providers in Germany
Table 10.3 List of Indian Hospitals or Organizations Providing Precision Medicine Related Services
Table 11.1 Allscripts Healthcare Solutions, Inc.: Recent Developments
Table 11.2 Cota, Inc.: Recent Developments
Table 11.3 CureMatch, Inc.: Recent Developments
Table 11.4 DrChrono Inc.: Recent Developments
Table 11.5 F. Hoffmann-La Roche AG: Recent Developments
Table 11.6 GenomOncology LLC: Recent Developments
Table 11.7 Interpreta, Inc.: Recent Developments
Table 11.8 Illumina, Inc.: Collaborations, Agreements, and Partnerships
Table 11.9 Illumina, Inc.: Acquisition
Table 11.10 IBM Corporation: Recent Developments
Table 11.11 Koninklijke Philips N.V.: Recent Developments
Table 11.12 LunaDNA Inc.: Recent Developments
Table 11.13 Navican Genomics, Inc.: Recent Developments
Table 11.14 N-of-One, Inc.: Recent Developments
Table 11.15 NantHealth, Inc.: Recent Developments
Table 11.16 Orion Health Group Limited: Recent Developments
Table 11.17 QIAGEN N.V.: Acquisition
Table 11.18 QIAGEN N.V.: Collaborations, Partnership, and Agreement
Table 11.19 Sophia Genetics SA: Recent Developments
Table 11.20 Syapse, Inc.: Recent Developments
Table 11.21 SAP SE: Recent Developments
Table 11.22 Tempus Labs, Inc.: Recent Developments
Table 11.23 Verily Life Sciences LLC: Recent Developments

List of Figures

Figure 1 The shift from One-Size-Fits-All to targeted Therapy (Precision Medicine)
Figure 2 Percentage of NGS Costs (by Function), 2018 and 2026
Figure 3 Impact Analysis of Market Dynamics
Figure 4 Global NGS Informatics and Clinical Genomics Market, 2018
Figure 5 Share of Key Developments and Strategies
Figure 6 Global NGS Informatics and Clinical Genomics Market (by Product)
Figure 7 Global NGS Informatics and Clinical Genomics Market (by End User)
Figure 8 Global NGS Informatics and Clinical Genomics Market (by Region)
Figure 9 The Future of Global NGS Informatics and Clinical Genomics Market)
Figure 1.1 The Flow of Genomic Data Across the NGS Informatics and Clinical Genomics Value-Chain
Figure 1.2 Different Stages of NGS Data Analysis
Figure 1.3 Approach to Precision Medicine
Figure 1.4 Evolution of Precision Medicine Technology
Figure 1.5 A Plethora of Data Types Catoring to Precision Medicine
Figure 1.6 The Flow of Genomic Data is the Major Barrier in its own inhibition
Figure 2.1 Market Dynamics of Global NGS Informatics and Clinical Genomics Market
Figure 2.2 Plummeting Cost of Genome Sequencing
Figure 2.3 Timeline of the Key Population Genomics Research Projects
Figure 3.1 Key Strategies Employed by Companies in NGS informatics and Clinical Genomics, 2014-2018
Figure 3.2 Key Strategies Employed by Companies in NGS informatics and Clinical Genomics, 2014-2018
Figure 4.1 Porter’s Five Forces Analysis
Figure 4.2 Bargaining Power of Suppliers: Overall Impact
Figure 4.3 Bargaining Power of Buyers: Overall Impact
Figure 4.4 Threat of New Entrant: Overall Impact
Figure 4.5 Threat of Substitute Products: Overall Impact
Figure 4.6 Intensity of Competitive Rivalry: Overall Impact
Figure 8.1 A holistic View of the Diverse Product Segments of Global NGS Informatics Market
Figure 8.2 Global LIMS Market, 2017-2028
Figure 8.3 Standard Workflow of a Laboratory Information System
Figure 8.4 Global NGS Informatics Services Market, 2017-2028
Figure 8.5 First stage of NGS data analysis: Primary analysis: Base calling.
Figure 8.6 Second Stage of NGS Data Analysis: Secondary analysis: Read Alignment and Variant Calling.
Figure 8.7 Global Commercial Primary and Secondary Analysis Tools Market, $Million, 2017-2028
Figure 8.8 Global NGS Data Storage and Computing Market, 2017-2028 ($Million)
Figure 8.9 Global Interpretation and Reporting Tools Market, $Million, 2017-2028
Figure 8.10 Workflow of NGS Tertiary Analysis: Interpretation of NGS Data
Figure 9.1 Global NGS Informatics and Clinical Genomics End User Market (Academic and Research Institutes), $Million, 2017-2028
Figure 9.2 Global NGS Informatics and Clinical Genomics End User Market (Biopharmaceutical Industries), $Million, 2017-2028
Figure 9.3 Global NGS Informatics and Clinical Genomics End User Market (Diagnostic Industry), $Million, 2017-2028
Figure 9.4 Global NGS Informatics and Clinical Genomics End User Market (Government Agencies), $Million, 2017-2028
Figure 9.5 Global NGS Informatics and Clinical Genomics Market (Hospitals and Clinics) $Million, 2017-2028
Figure 10.1 Global NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.2 North America NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.3 U.S. NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.4 The U.S. Laboratory Information Management System (LIMS) Market , $Million, 2017-2028
Figure 10.5 The U.S. NGS Informatics Services Market , $Million, 2017-2028
Figure 10.6 The U.S. Commercial Primary and Secondnary Data Analysis Tools Market, $Million, 2017-2028
Figure 10.7 The U.S. Storage and Computing Solutions Market, $Million, 2017-2028
Figure 10.8 The U.S. Interpretation and Reporting Tools Market, $Million, 2017-2028
Figure 10.9 The U.S. NGS Informatics and Clinical Genomics End Users Market (By Academics and Research Institutes), $Million, 2017-2028
Figure 10.10 The U.S. NGS Informatics and Clinical Genomics End Users Market (By Biopharmaceutical Industry), $Million, 2017-2028
Figure 10.11 The U.S. NGS Informatics and Clinical Genomics End Users Market (By Diagnostic Industry), $Million, 2017-2028
Figure 10.12 The U.S. NGS Informatics and Clinical Genomics End Users Market (By Government Agencies), $Million, 2017-2028
Figure 10.13 The U.S. NGS Informatics and Clinical Genomics End Users Market (By Hospitals and Clinics), $Million, 2017-2028
Figure 10.14 Distribution of the Financial Support Provided by the U.S. Government, 2015
Figure 10.15 Canada NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.16 Canada NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.17 Europe NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.18 Germany NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.19 Germany NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.20 U.K. NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.21 U.K. NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.22 Italy NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.23 Italy NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.24 France NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.25 France NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.26 Spain NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.27 Spain NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.28 Rest-of-Europe NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.29 Asia-Pacific NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.30 India NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.31 India NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.32 China NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.33 China NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.34 Japan NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.35 Japan NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.36 South Korea NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.37 Australia NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.38 Australia NGS Informatics and Clinical Genomics End Users Market, $Million, 2017-2028
Figure 10.39 Singapore NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.40 Rest-of-Asia-Pacific NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.41 The RoW Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 10.42 Brazil NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.43 Mexico NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.44 Russia NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.45 Israel NGS Informatics and Clinical Genomics Market Revenue, $Million, 2017-2028
Figure 10.46 Other countries in “RoW” NGS Informatics and Clinical Genomics Market, $Million, 2017-2028
Figure 11.1 Shares of Key Company Profiles
Figure 11.2 Allscripts Healthcare Solutions, Inc.: Product/Service Offerings
Figure 11.3 Allscripts Healthcare Solutions, Inc.: Precision Medicine Solutions
Figure 11.4 Allscripts Healthcare Solutions, Inc.: Overall Financials, 2015-2017
Figure 11.5 Allscripts Healthcare Solutions, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 11.6 Allscripts Healthcare Solutions, Inc.: Net Revenue (by Region), 2015-2017
Figure 11.7 Allscripts Healthcare Solutions, Inc.: Global Presence
Figure 11.8 Allscripts Healthcare Solutions, Inc.: SWOT Analysis
Figure 11.9 Cota, Inc.: Product Portfolio
Figure 11.10 Cota, Inc.: Global Presence
Figure 11.11 Cota, Inc.: SWOT Analysis
Figure 11.12 CureMatch, Inc.: Product/Service Offerings
Figure 11.13 Merit Medical Systems, Inc: Global Presence
Figure 11.14 CureMatch, Inc.: SWOT Analysis
Figure 11.15 DrChrono Inc.: Overall Product Portfolio
Figure 11.16 DrChrono Inc.: Healthcare IT for Precision Medicine Product Portfolio
Figure 11.17 DrChrono Inc.: Global Presence
Figure 11.18 DrChrono Inc.: SWOT Analysis
Figure 11.19 Epic Systems Corporation: Product/Service Offerings
Figure 11.20 Epic Systems Corporation: Precision Medicine Product Portfolio
Figure 11.21 Epic Systems Corporation: Global Presence
Figure 11.22 Epic Systems Corporation: SWOT Analysis
Figure 11.23 F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 11.24 F. Hoffmann-La Roche AG: Precision Medicine Product Portfolio
Figure 11.25 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 11.26 F. Hoffmann-La Roche AG: Net Revenue (by Region), 2015-2017
Figure 11.27 F. Hoffmann-La Roche AG: Net Revenue (by Business Segment),2015-2017
Figure 11.28 F. Hoffmann-La Roche AG: Global Presence
Figure 11.29 F. Hoffmann-La Roche AG: SWOT Analysis
Figure 11.30 GenomOncology, LLC: Product Portfolio
Figure 11.31 GenomOncology, LLC: Global Presence
Figure 11.32 GenomOncology LLC: SWOT Analysis
Figure 11.33 Interpreta, Inc.: Product Portfolio
Figure 11.34 Interpreta, Inc.: Global Presence
Figure 11.35 Interpreta, Inc.: SWOT Analysis
Figure 11.36 Illumina, Inc.: Overall Product Portfolio
Figure 11.37 Illumina, Inc.: Product Portfolio for Global NGS Informatics and Clinical Genomics Market
Figure 11.38 Illumina, Inc.: Overall Financials, 2015-2017
Figure 11.39 Illumina, Inc.: Net Revenue (by Region), 2015-2017
Figure 11.40 Illumina, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 11.41 Illumina, Inc.: Global Presence
Figure 11.42 Illumina, Inc.: SWOT Analysis
Figure 11.43 IBM Corporation: Product/Service Offerings
Figure 11.44 IBM Corporation: Precision Medicine Product Portfolio
Figure 11.45 IBM Corporation: Overall Financials (2015-2017)
Figure 11.46 IBM Corporation: Net Revenue (by Business Segment), 2015-2017
Figure 11.47 IBM Corporation: Net Revenue (by Region), 2015-17
Figure 11.48 IBM Corporation: Global Presence
Figure 11.49 IBM Corporation: SWOT Analysis
Figure 11.50 Koninklijke Philips N.V.: Product/Service Offerings
Figure 11.51 Koninklijke Philips N.V.: Precision Medicine Product Portfolio
Figure 11.52 Koninklijke Philips N.V.: Overall Financials, 2015-2017
Figure 11.53 Koninklijke Philips N.V.: Net Revenue (by Business Segments), 2015-2017
Figure 11.54 Koninklijke Philips N.V.: Net Revenue (by Region), 2015-2017
Figure 11.55 Koninklijke Philips N.V.: Global Presence
Figure 11.56 Koninklijke Philips N.V.: SWOT Analysis
Figure 11.57 LunaDNA Inc.: Product/Service Offerings
Figure 11.58 LunaDNA Inc.: Global Presence
Figure 11.59 LunaDNA Inc.: SWOT Analysis
Figure 11.60 Navican Genomics, Inc.: Product/Service Offerings
Figure 11.61 Navican Genomics, Inc.: Global Presence
Figure 11.62 Navican Genomics, Inc.: SWOT Analysis
Figure 11.63 N-of-One, Inc.: Product/Service Offerings
Figure 11.64 N-of-One, Inc.: Global Presence
Figure 11.65 N-of-One, Inc.: SWOT Analysis
Figure 11.66 NantHealth, Inc.: Product/Service Offerings
Figure 11.67 NantHealth, Inc.: Precision Medicine Product Portfolio
Figure 11.68 NantHealth, Inc.: Overall Financials
Figure 11.69 NantHealth, Inc.: Net Revenue (by Product Segments), 2015-2017
Figure 11.70 NantHealth, Inc.: Global Presence
Figure 11.71 NantHealth, Inc.: SWOT Analysis
Figure 11.72 Orion Health Group Limited: Product/Service Offerings
Figure 11.73 Orion Health Group Limited: Precision Medicine Product Portfolio
Figure 11.74 Orion Health Group Limited: Overall Financials, 2016-2018
Figure 11.75 Orion Health Group Limited: Net Revenue (by Product/Service Category), 2016-2018
Figure 11.76 Orion Health Group Limited: Net Revenue (by Region), 2016-2018
Figure 11.77 Orion Health Group Limited: Global Presence
Figure 11.78 Orion Health Group Limited: SWOT Analysis
Figure 11.79 QIAGEN N.V.: Overall Product Portfolio
Figure 11.80 QIAGEN N.V.: Product Portfolio for Global NGS Informatics and Clinical Genomics Market
Figure 11.81 QIAGEN N.V.: Overall Financials, 2015-2017
Figure 11.82 QIAGEN N.V.: Net Revenue (by Business Segment), 2015-2017
Figure 11.83 QIAGEN N.V.: Net Revenue (by Region), 2015-2017
Figure 11.84 QIAGEN N.V.: Global Presence
Figure 11.85 QIAGEN N.V.: SWOT Analysis
Figure 11.86 Sophia Genetics SA: Product/Service Offerings
Figure 11.87 Sophia Genetics SA: Global Presence
Figure 11.88 Sophia Genetics SA: SWOT Analysis
Figure 11.89 Syapse, Inc.: Product/Service Offerings
Figure 11.90 Syapse, Inc.: Global Presence
Figure 11.91 Syapse, Inc.: SWOT Analysis
Figure 11.92 SAP SE: Product/Service Offerings
Figure 11.93 SAP SE: Precision Medicine Product Portfolio
Figure 11.94 SAP SE: Overall Financials, 2015-2017
Figure 11.95 SAP SE: Net Revenue (by Business Segments), 2015-2017
Figure 11.96 SAP SE: Net Revenue (by Region), 2015-2017
Figure 11.97 SAP SE: Global Presence
Figure 11.98 SAP SE: SWOT Analysis
Figure 11.99 Tempus Labs, Inc.: Product Portfolio
Figure 11.100 Tempus Labs, Inc.: Global Presence
Figure 11.101 Tempus Labs, Inc.: SWOT Analysis
Figure 11.102 Verily Life Sciences LLC: Projects
Figure 11.103 Verily Life Sciences LLC: Precision Medicine Product Portfolio
Figure 11.104 Verily Life Sciences LLC: Global Presence
Figure 11.105 Verily Life Sciences LLC: SWOT Analysis
Figure 12.1 Scope of the Global NGS Informatics and Clinical Genomics Market
Figure 12.2 Global NGS informatics and Clinical Genomics Market: Research Methodology
Figure 12.3 Primary Research
Figure 12.4 Secondary Research
Figure 12.5 Data Triangulation
Figure 12.6 Top-Down Approach (Segment Wise Analysis)
Figure 17.7 Bottom-Up Approach (Segment Wise Analysis)
Figure 12.8 Assumptions and Limitations
Figure 12.9 Considered Factors for Data Prediction & Modeling